Literature DB >> 20151344

[Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report].

Thomas Sitte1.   

Abstract

Severe dyspnoea is the most threatening symptom of the dying and one of the main reasons for undesirable hospitalisation in end of life. Especially in home care there is a need for a noninvasive, safe and highly effective method for symptom control. Fentanyl is an appropriate drug because of its fast onset and short duration of action. Since 2003 medicated the Palliative Net Easthessia (PNO) more than 600 home care patients with nasal Fentanyl (naF). The method is simple and the user should bear in mind that the substance is highly effective. Both physician and pharmacist should inform themselves adequately before the first use about the basics of the manufacturing and use. Two typical case reports will be shown. Clinical experience let us assume that intranasal administration against dyspnoea is not inferior to the intravenous symptom control. In ambulant care caused by the use of the caring relatives or the patients themselves non-invasivity is a great advantage. Prospective studies are in need to prove the method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20151344     DOI: 10.1007/s10354-009-0724-2

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  15 in total

1.  An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.

Authors:  G Zeppetella
Journal:  J Pain Symptom Manage       Date:  2000-10       Impact factor: 3.612

Review 2.  Drug metabolism in the nasal mucosa.

Authors:  M A Sarkar
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

3.  Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Vincenza Snow; Paul Shekelle; Donald E Casey; J Thomas Cross; Douglas K Owens; Paul Dallas; Nancy C Dolan; Mary Ann Forciea; Lakshmi Halasyamani; Robert H Hopkins; Paul Shekelle
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

4.  Intranasal fentanyl for episodic breathlessness.

Authors:  Thomas Sitte; Claudia Bausewein
Journal:  J Pain Symptom Manage       Date:  2008-10-26       Impact factor: 3.612

5.  The systemic availability of buprenorphine administered by nasal spray.

Authors:  J Eriksen; N H Jensen; M Kamp-Jensen; H Bjarnø; P Friis; D Brewster
Journal:  J Pharm Pharmacol       Date:  1989-11       Impact factor: 3.765

6.  Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea.

Authors:  Patrick J Coyne; Ramakrishnan Viswanathan; Thomas J Smith
Journal:  J Pain Symptom Manage       Date:  2002-02       Impact factor: 3.612

Review 7.  Opioids for the palliation of breathlessness in terminal illness.

Authors:  A L Jennings; A N Davies; J P Higgins; K Broadley
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 8.  Nasal administration of opioids for pain management in adults.

Authors:  O Dale; R Hjortkjaer; E D Kharasch
Journal:  Acta Anaesthesiol Scand       Date:  2002-08       Impact factor: 2.105

9.  Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study.

Authors:  Lona L Christrup; David Foster; Lars D Popper; Tine Troen; Richard Upton
Journal:  Clin Ther       Date:  2008-03       Impact factor: 3.393

10.  Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea.

Authors:  Amy P Abernethy; David C Currow; Peter Frith; Belinda S Fazekas; Annie McHugh; Chuong Bui
Journal:  BMJ       Date:  2003-09-06
View more
  2 in total

1.  Role of intranasal fentanyl in breakthrough pain management in cancer patients.

Authors:  Wojciech Leppert
Journal:  Cancer Manag Res       Date:  2010-09-30       Impact factor: 3.989

2.  Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions.

Authors:  Lucas Pieper; Julia Wager; Boris Zernikow
Journal:  BMC Palliat Care       Date:  2018-09-10       Impact factor: 3.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.